stockrowTransMedics Group, Inc.
TMDX Healthcare Medical Devices
TransMedics Group, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $605.5 million, up 37.1% from fiscal 2024.
- Revenue
- +41.2%
- EPS
- −31.0%
- Free cash flow
- −55.4%
- Total debt
- −89.3%
Quarter to September 2026, against a year earlier
Follow TMDX
Alert me
TransMedics Group, Inc. (TMDX) EPS (diluted)
TransMedics Group, Inc.'s EPS (diluted) for fiscal 2025 was $4.87, up 382.2% from $1.01 in fiscal 2024. Over the twelve months to 30 September 2026 it was $3.69. Over the past ten years it has ranged from −$17.48 (fiscal 2018) to $4.87 (fiscal 2025) — the current reading is the highest in ten years. EPS (diluted) has risen for 4 consecutive fiscal years. TransMedics Group, Inc. ranks 12th of 147 Medical Devices companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | $4.87 | 382.18% |
| FY2024 | $1.01 | — |
| FY2023 | −$0.77 | — |
| FY2022 | −$1.23 | — |
| FY2021 | −$1.60 | — |
| FY2020 | −$1.16 | — |
| FY2019 | −$2.36 | — |
| FY2018 | −$17.48 | — |
| FY2017 | −$1.04 | — |
| FY2016 | −$1.21 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | $0.46 | 12.20% |
| Jun 2026 | $0.41 | 105.00% |
| Mar 2026 | $0.20 | (92.37%) |
| Dec 2025 | $2.62 | 296.97% |
| 31 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| UFPT UFP Technologies, Inc. compare | $9.81 |
| TMDX TransMedics Group, Inc. | $3.69 |
| INSP Inspire Medical Systems, Inc. compare | $3.44 |
| BFLY Butterfly Network, Inc. compare | −$0.21 |
| NEOG Neogen Corporation compare | −$0.25 |
| AXGN AxoGen, Inc. compare | −$0.65 |
| NVCR NovoCure Limited compare | −$1.06 |
| ESTA Establishment Labs Holdings Inc. compare | −$1.31 |
| ALMR Alamar Biosciences, Inc. compare | −$2.77 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on TMDX
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement